Mometasone furoate
Asmanex, Breezhaler, Dulera, Mometasone Furoate, Nasonex, Ryaltris, Sinuva (mometasone furoate) is a small molecule pharmaceutical. Mometasone furoate was first approved as Elocon on 1987-04-30. It is used to treat allergic rhinitis perennial, facial dermatoses, foot dermatoses, hand dermatoses, and inflammation amongst others in the USA. It has been approved in Europe to treat asthma.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| allergy | New Drug Application | 2024-08-29 |
| allergy nasal | New Drug Application | 2024-08-28 |
| asmanex | New Drug Application | 2022-11-14 |
| asmanex hfa | New Drug Application | 2024-11-20 |
| basic care allergy | New Drug Application | 2024-08-28 |
| childrens nasonex | New Drug Application | 2024-08-28 |
| dulera | New Drug Application | 2023-03-24 |
| elocon | New Drug Application | 2010-08-31 |
| hyaluronic acid sodium salt 2% / mometasone furoate 0.1% / niacinamide 4% | unapproved drug other | 2019-05-21 |
| leader allergy nasal | New Drug Application | 2024-12-02 |
Show 9 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
MOMETASONE FUROATE / OLOPATADINE HYDROCHLORIDE, RYALTRIS, GLENMARK SPECIALTY | |||
| 2025-01-13 | NP | ||
FORMOTEROL FUMARATE / MOMETASONE FUROATE, DULERA, ORGANON LLC | |||
| 2023-02-12 | PED | ||
MOMETASONE FUROATE, ASMANEX HFA, ORGANON LLC | |||
| 2023-02-12 | PED | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Mometasone Furoate, Sinuva, Intersect Ent Inc | |||
| 10232152 | 2034-11-24 | DP | U-2272 |
| 10406332 | 2034-03-13 | DP | |
| 8763222 | 2032-02-08 | DP | |
| 10357640 | 2031-10-03 | U-2272 | |
| 8025635 | 2027-06-12 | DP | U-2272 |
| 7544192 | 2026-11-29 | U-2272 | |
| 9585681 | 2026-04-04 | U-2272 | |
| 7662141 | 2024-03-12 | U-2272 | |
| 7713255 | 2024-03-12 | U-2272 | |
| 7951130 | 2024-03-12 | U-2272 | |
| 7951131 | 2024-03-12 | U-2272 | |
| 7951133 | 2024-03-12 | U-2272 | |
| 8109918 | 2024-03-12 | U-2272 | |
| Mometasone Furoate / Olopatadine Hydrochloride, Ryaltris, Glenmark Specialty | |||
| 9078923 | 2034-09-04 | DP | U-3297 |
| 9370483 | 2034-09-04 | DP | |
| 9750754 | 2034-09-04 | DP | U-3297 |
| 9937189 | 2034-09-04 | DP | |
| 10016443 | 2034-09-04 | U-3297 | |
| 10376526 | 2034-09-04 | DP | |
| 10517880 | 2034-09-04 | DP | U-3297 |
| 10548907 | 2034-09-04 | U-3297 | |
| 10561672 | 2034-09-04 | DP | |
| 10646500 | 2034-09-04 | U-3297 | |
| 10758550 | 2034-09-04 | U-3296 | |
| 10765686 | 2034-09-04 | U-3295 | |
| 11400101 | 2034-09-04 | U-3297 | |
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| J7402 | Mometasone furoate sinus implant, (sinuva), 10 micrograms |
Clinical
Clinical Trials
324 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 8 | 13 | — | 4 | 25 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | 3 | — | — | 4 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | — | 1 | 2 | — | — | 3 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic rhinitis | D065631 | — | J30.9 | — | 1 | — | — | — | 1 |
| Rhinitis | D012220 | EFO_0008521 | J31 | — | 1 | — | — | — | 1 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mometasone furoate |
| INN | — |
| Description | Mometasone furoate is a 2-furoate ester, a steroid ester, an 11beta-hydroxy steroid, a 20-oxo steroid, an organochlorine compound and a 3-oxo-Delta(1),Delta(4)-steroid. It has a role as an anti-inflammatory drug and an anti-allergic agent. It is functionally related to a mometasone. |
| Classification | Small molecule |
| Drug class | Corticosteroid; Glucocorticoid |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl |
Identifiers
| PDB | — |
| CAS-ID | 83919-23-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1161 |
| ChEBI ID | 47564 |
| PubChem CID | 441336 |
| DrugBank | DB00764 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Nasonex – Organon
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Nasonex – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Asmanex – Organon
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Dulera – Organon
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Dulera – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Mometasone furoate
+
Formoterol
+
Mometasone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Mometasone furoate
+
Mometasone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
21,433 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use